Review Article

The Prevalence of Migraine in Inflammatory Bowel Disease, a Systematic Review and Meta-Analysis

Abstract

Background: Patients with inflammatory bowel disease (IBD) suffer from a wide range of comorbidities such as migraine. In studies, the prevalence of migraine in cases with IBD was reported differently. The goal of this systematic review and meta-analysis was to estimate the pooled prevalence of migraine in IBD cases. Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched the gray literature including references of the included studies and conference abstracts which were published up to May 2021. Cross-sectional studies were included. Results: The literature search revealed 840 articles, and after deleting duplicates, 650 remained. For the meta-analysis, 10 studies were included. Totally, 62,554 patients were evaluated. The pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15-22%). The pooled prevalence of migraine in ulcerative colitis (UC) was 10% (95% CI: 4-15%) $(I^2 = 99.8\%, P < 0.001)$. The pooled prevalence of migraine in the Crohn's disease (CD) group was 24% (95% CI: 17–30%) ($I^2 = 98.8\%$, P < 0.001). The pooled odds of developing migraine in IBD cases was 1.51 (95% CI: 1–2.27) ($I^2 = 90.8\%$, P < 0.001). Conclusions: The result of this systematic review and meta-analysis showed that the pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15-22%).

Keywords: *Inflammatory bowel disease, migraine disorders, prevalence*

Introduction

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a complex chronic disease affecting primarily the gastrointestinal tract along with other organs.^[1,2] The prevalence of IBD is reported as 0.4% in developed countries.^[1]

It is well known that IBD is associated with a number of extra-intestinal diseases. Some of them are complications of the disease process such as venous thromboembolism (VTE), whereas others are considered as extra-gastrointestinal (GI) manifestations.^[3]

Extra-GI manifestations include articular, cutaneous, neurological, and ocular involvement with prevalence of 40%.^[4,5]

Previous studies demonstrated that the prevalence of neurological manifestations in IBD cases ranges between 25 and 37.5%.^[6-8]

Migraine is a chronic disorder affecting women more than men and is the first

cause of disability under 50.^[9] Its origin is not clear as brain–gut interactions are considered as pathogenesis of the migraine in patients with IBD^[2] as well as side effects of immunosuppressive agents.

Previous studies demonstrate that the prevalence of migraine in patients with IBD is more than the general population and the odds are increased by 2.6-fold.^[10,11]

As the prevalence of migraine in cases with IBD is reported variously, we designed this systematic review and meta-analysis to estimate the pooled prevalence of migraine in IBD cases.

Methods

Literature search

Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched the gray literature including references of the included studies and conference abstracts which were published up to May 2021.

How to cite this article: Olfati H, Mirmosayyeb O, Hosseinabadi AM, Ghajarzadeh M. The prevalence of migraine in inflammatory bowel disease, a systematic review and meta-analysis. Int J Prev Med 2023;14:66.

Hamide Olfati, Omid Mirmosayyeb^{1,2,3}, Ali Mahdi Hosseinabadi², Mahsa Ghajarzadeh^{3,4}

Department of Endocrinology, Razi Hospital, Qazvin, ¹Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, ²Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, ³Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN). *Tehran*, ⁴*Multiple Sclerosis* Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Address for correspondence: Dr. Mahsa Ghajarzadeh, Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran. E-mail: m.ghajarzadeh@gmail. com



© 2023 International Journal of Preventive Medicine | Published by Wolters Kluwer - Medknow

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Inclusion criteria

We included cross-sectional studies which had reported the number of patients with IBD who had migraine diagnosis.

Exclusion criteria

Letters to the editor, case-control, case reports, and cross-sectional studies which had no clear data regarding the prevalence of migraine in enrolled cases were excluded.

Data search and extraction

The search strategy included the MeSH and text words as ("Migraine Disorder" OR (Migraine AND Disorder) OR "Migraine Disorders" OR (Migraine AND Disorders) OR "Migraine" OR "Migraines" OR "Migraine Headache" OR (Migraine AND Headache) OR "Migraine Headaches" OR (Migraine AND Headache)) AND ("Inflammatory Bowel Disease" OR "Inflammatory Bowel Diseases" OR (Inflammatory AND Bowel Disease) OR (Inflammatory AND Bowel Diseases) OR "Idiopathic Proctocolitis" OR (Idiopathic AND Proctocolitis) OR "Ulcerative Colitis" OR (Ulcerative AND Colitis) OR "Colitis Gravis" OR (Colitis AND Gravis) OR "Crohn's Enteritis" OR (Crohn's AND Enteritis) OR "Regional Enteritis" OR (Regional AND Enteritis) OR "Crohn's Disease" OR (Crohn's AND Disease) OR "Regional Ileitis" OR (Ileitis AND Regional) OR "Terminal Ileitis" OR (Terminal AND Ileitis) OR "Ileocolitis" OR "Granulomatous Colitis" OR (Granulomatous Colitis) "Granulomatous Enteritis" AND OR OR (Granulomatous AND Enteritis)). Two independent researchers independently evaluated the articles.

We extracted data regarding the total number of participants, first author, publication year, the country of origin, mean age, sex frequency, and number with migraine.

Risk of bias assessment

We evaluated the risk of potential bias using the NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE (adapted for cross-sectional studies).^[12,13] It is used for evaluating the quality of non-randomized studies including three sections (selection, comparability, and outcome). It has totally seven questions. The maximum total score could be 10 [Tables 2 & 3].

Statistical analysis

All statistical analyses were performed using STATA (Version 14.0; Stata Corp LP, College Station, TX, USA).

To determine heterogeneity, inconsistency (I^2) was calculated.

As the heterogeneity between results of included studies was more than 50%, we used the random effects model. Pooled prevalence of migraine in IBD cases as well as UC and Crohn's subgroups is reported with 95% CI.

Results

The literature search revealed 840 articles, and after deleting duplicates, 650 remained. For the meta-analysis, 10 studies were included [Figure 1].

Totally, 62,554 patients were evaluated. The mean age ranged from 17 to 53 years [Table 1].

The pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15–22%) ($I^2 = 99.2\%$, P < 0.001) [Figure 2].

The pooled prevalence of migraine in controls was 6% (95% CI: 4–8%) (I2: 99.9%, P < 0.001) [Figure 3].

The pooled prevalence of migraine in UC was 10% (95% CI: 4–15%) ($I^2 = 99.8\%$, P < 0.001) [Figure 4].

The pooled prevalence of migraine in CD was 24% (95% CI: 17–30%) ($I^2 = 98.8\%$, P < 0.001) [Figure 5].

The pooled odds of developing migraine in IBD cases was 1.51 (95% CI: 1–2.27) ($I^2 = 90.8\%$, P < 0.001) [Figure 6].

Discussion

To our knowledge, this is the first systematic review and meta-analysis evaluating the prevalence of migraine in patients with IBD. The results of this study showed that the pooled prevalence of migraine in IBD cases is 19%, whereas the prevalence is higher in CD cases than UC ones (24% vs 10%). The results also show that the odds of developing migraine are significantly higher in IBD cases when compared with controls (1.5-fold).

In a study in Iran, Cheraghi *et al.*^[8] reported the prevalence of migraine in 21.3% of IBD cases compared to 8.8% of controls. In another study which was conducted by Dimitrova *et al.*,^[11] the prevalence of migraine was reported as 14% in IBD cases and 6% in controls.

Ghersin *et al.*^[17] assessed 295 UC and 595 CD cases and reported no association between migraine and IBD. In their study, none of the UC cases and only 8 CD cases had migraine.




Figure 1: Flow diagram of including studies

[Downloaded free from http://www.ijpvmjournal.net on Tuesday, May 30, 2023, IP: 176.102.246.29]

Olfati, et al.: Migraine in inflammatory bowel disease

r of ne 105 105 9 9 9 9 9 8 8 8 8 8 8 8 8 8 8 8 8					E	Table 1: Basic characteristics of the included studies	Basic	chara	cterist	ics of	the inc	cluded	stud	ies						
Publication study article Age Number patients patients F M T CD UC Total In	Author	I	Year of	Year of	Type of	Demo	graphi	c featu	res	Numb	er of I	BD	Num	ber of	IBD			Controls data	s data	
F M T CD UC Total In			publication	study	article	Age	Z	umber		p:	atients		mig pat	raine ients	duration		Dem	Demographic		Number of
Hungary2019 $2005-2016$ RetrospectiveNA75758Brazil 2020 $2015-2016$ cross-sectional, $43(1)$ 83 72 155 75 80 155 30 23 53 Brazil 2017 2017 2014 cross-sectional, $56(28)$ 2684 2107 4791 4791 -105Furkey 2016 2012 cross-sectional $55(12)$ 26 25 51 <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>ы</th> <th>Μ</th> <th>F</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>Age</th> <th>Ĩ</th> <th>W</th> <th>F</th> <th>Migraine in control</th>							ы	Μ	F							Age	Ĩ	W	F	Migraine in control
Brazil 2020 2015-2016 cross-sectional, 43 (1) 83 72 155 75 80 155 30 23 53 </td <td>J. Tajti J.</td> <td>r Hungary</td> <td></td> <td>2005-201</td> <td>6 Retrospective abstract</td> <td>NA</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>75</td> <td>75</td> <td>1</td> <td>- ×</td> <td>1</td> <td>1</td> <td></td> <td>1</td> <td>1</td> <td></td>	J. Tajti J.	r Hungary		2005-201	6 Retrospective abstract	NA	1	1	1	1	75	75	1	- ×	1	1		1	1	
Switzerland 2017 2014 cross-sectional 56 (28) 2684 2107 4791 - - 4791 - - 105 Turkey 2016 2012 cross-sectional 35 (12) 26 25 51 51 5 5 9 United 2016 1987-2011 cohort 47.2 29814 26283 56097 18204 2130 1892 4380 a United 2013 2010-2011 Prospective 36.5 58 53 111 - - 111 - - 111 - - 25 States 2009 2006 Prospective 40.3 77 23 100 66 27 100 24 4 28 States 2019 2004-2016 60071 17.1 318 573 891 595 296 891 8 0 8 Iranel 2019 204-2016 60071	Leitão <i>et al</i> . ^[14]	Brazil		2015-201		43 (1)	83	72	155	75						46 (2)	35	99	101	21
Turkey 2016 2012 cross-sectional 35 (12) 26 25 51 51 51 35 5 9 United 2016 1987-2011 cohort 47.2 29814 26283 56097 18204 130 1892 4380 Kingdom 2013 2010-2011 Prospective 36.5 58 53 111 - - 111 - - 25 States 2009 2006 Prospective 40.3 77 23 100 66 27 100 24 4 28 United 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Itan 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 17 17 Itan 2016 2014 Cross-scectional 35 </td <td>Bähler^{[15}</td> <td>¹ Switzerland</td> <td></td> <td>2014</td> <td></td> <td>56 (28)</td> <td>2684</td> <td></td> <td>4791</td> <td>ı</td> <td>1</td> <td>1791</td> <td>ı</td> <td>- 10:</td> <td>1</td> <td>44</td> <td>575943</td> <td>575943 538695</td> <td>1114638</td> <td>12261</td>	Bähler ^{[15}	¹ Switzerland		2014		56 (28)	2684		4791	ı	1	1791	ı	- 10:	1	44	575943	575943 538695	1114638	12261
United 2016 1987-2011 cohort 47.2 29814 26283 56097 18204 27108 56097 130 1892 430 Kingdom a United 2013 2010-2011 Prospective 36.5 58 53 111 - - 111 - - 25 a United 2009 2006 Prospective 40.3 77 23 100 66 27 100 24 4 28 Vinted 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Iran 2016 2014-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Iran 2016 2014-2016 cohort 17.1 318 573 891 595 296 801 8 0 8 Iran 2016 2014	Anadol Kelleci <i>et al.</i> ^[16]	Turkey	2016	2012		35 (12)	26	25	51	51	I	51	35	- 9	29.17 (10.24)	35 (9)	27	24	51	21
a United 2013 2010-2011 Prospective 36.5 58 53 111 - - 111 - - 25 States 2009 2006 Prospective 40.3 77 23 100 66 27 100 24 4 28 United 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Iran 2016 2014 Cross-sectional 35 33 47 80 18 62 80 8 0 8 Iran 2016 2014 Cross-sectional 35 33 47 80 18 62 80 - 17 France 2017 2014-2015 Cohort 40.1 113 90 203 129 7 <td< td=""><td>Card et al.^[3]</td><td></td><td></td><td>1987-201</td><td>1 cohort</td><td></td><td>29814 2</td><td>26283 5</td><td>56097 1</td><td>18204 2</td><td>27108 5</td><td>6097 1</td><td>430 18</td><td>392 438</td><td></td><td>47.2</td><td>149030</td><td>131352</td><td>47.2 149030 131352 280,382</td><td>19376</td></td<>	Card et al. ^[3]			1987-201	1 cohort		29814 2	26283 5	56097 1	18204 2	27108 5	6097 1	430 18	392 438		47.2	149030	131352	47.2 149030 131352 280,382	19376
United 2009 2006 Prospective 40.3 77 23 100 66 27 100 24 4 28 States (14.9) (14.9) (14.9) (14.9) (14.9) 891 595 296 891 8 0 8 Israel 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Iran 2016 2014 Cross-sectional 35 33 47 80 18 62 80 - 17 France 2017 2014-2015 Cohort 40.1 113 90 203 129 73 - 17	Dimitrov et al.[11]	a United States		2010-201	1 Prospective	36.5	58	53	111	ı	ı	111	ı	- 25	·	47.8	109	69	178	25
Israel 2019 2004-2016 cohort 17.1 318 573 891 595 296 891 8 0 8 Iran 2016 2014 Cross-sectional 35 33 47 80 18 62 80 - 17 France 2017 2014-2015 Cohort 40.1 113 90 203 129 73 - 83	Ford et al. ^[10]		2009	2006	Prospective	40.3 (14.9)	LL	23	100	99	27				12.11 (10.19)	'	I	ı	I	ı
i Iran 2016 2014 Cross-sectional 35 33 47 80 18 62 80 17 France 2017 2014-2015 Cohort 40.1 113 90 203 129 73 203 83 (1)	Ghersin et al. ^[17]			2004-201	6 cohort	17.1	318	573				891	8	0 8	I	ı	I	ı	1,141,841	37,576
France 2017 2014-2015 Cohort 40.1 113 90 203 129 73 203 83 (1)	Cheragh et al. ^[8]	i Iran	2016	2014	Cross-sectional	35	33	47	80	18	62	80	ı	- 17	I	34.69	36	44	80	L
	Moisset <i>et al.</i> ^[2]			2014-201:	5 Cohort	40.1 (1)	113	90	203	129		203	,	- 83	10.5 (0.7)	ı.	1		,	

Olfati, et al.: Migraine in inflammatory bowel disease




Figure 2: The pooled prevalence of migraine in patients with IBD




Figure 3: The pooled prevalence of migraine in controls

Table 2: Quality assessment of included studies												
Name of the author		Questions Total sc										
		Selection	questions		Comparability questions	Out	come ques	tions				
	Q1	Q2	Q3	Q4	Q1	Q1	Q2	Q3				
Timothy R. Card	A*	B*	D	A*	A*	D	A*	A*	6			
Sutapa Ford	B*	С	B*	A*	С	С	A*	A*	5			
Itai Ghersin	A*	A*	D	A*	С	D	A*	A*	5			

In a cross-sectional study which was conducted by Ford *et al.*,^[10] the prevalence of migraine in IBD was 30% and the prevalence was higher in CD cases than in UC ones (36 vs 14%).

Peripheral and central nervous systems could be affected in patients with IBD.^[18,19]

Migraine is a disabling disease affecting women more than men which interferes with daily activity and sexual life and

Olfati, et al.: Migraine in inflammatory bowel disease




Figure 4: The pooled prevalence of migraine in UC




Figure 5: The pooled prevalence of migraine in CD

Name of the author				Quest	tions			Total score
		Sele	ction		Comparability	Outo	come	
	Q1	Q2	Q3	Q4	Q1	Q1	Q2	
Antônio M. F. Leitão	A*	A*	С	A**	-	C*	A*	6
Caroline Bähler	A*	A*	С	С	-	B**	A*	5
Ulker Anadol Kelleci	B*	A*	С	A**	B*	C*	A*	7
Alexandra K. Dimitrova	A*	A*	С	A**	-	C*	A*	6
Somaye Chehel Cheraghi	B*	A*	С	A**	A*	C*	A*	7
X. Moisset	A*	A*	С	A**	-	C*	A*	6

impairs the quality of sleep and life.^[20-22] Genetics plays an important role in developing migraine when there is a relationship between auto-immune disease and incidence of migraine, such as rheumatoid arthritis (RA), systemic lupus erythematosus, and multiple sclerosis.^[23-26] In a study which was conducted by AbdElaty ElSonbaty, the prevalence of migraine in patients with RA was estimated as 28%, and in a recent systematic review and meta-analysis, the pooled

prevalence of migraine in patients with multiple sclerosis was estimated as 31%.^[25,26]

The exact cause of migraine is unclear as neuronal and vascular mechanisms are involved.

The link between migraine and IBD could be clarified by the presence of systemic inflammation leading to neurogenic inflammation presenting with migraine.^[27]

Olfati, et al.: Migraine in inflammatory bowel disease




Figure 6: The pooled odds of developing migraine in IBD cases

Nowadays, the brain-gut axis is considered in the pathogenesis of some diseases. One of them is the serotonergic system.^[28] The level of serotonin is low between attacks and increases during migraine attacks, which shows a relationship between the low serotonin level and migraine incidence.^[29] It has been shown that in patients with UC, expression of the serotonin transporter in the gut epithelium is decreased and the level of serotonin is less than normal in the colon.^[30] Low serotonin levels could be the link between migraine and IBD.

Higher serum levels of cytokines in IBD cases than controls could flare headache. Moisset *et al.*^[2] showed that migraine is not associated with IBD clinical activity. They found that inflammatory activity is sufficient for migraine activity when there are no intestinal manifestations. The literature shows that C-reactive protein (CRP), matrix metallopeptidase 9 (MMP-9), cytokines, adhesion molecules, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), and inducible nitric oxide synthase (iNOS) have roles in developing migraine headache.^[31-33]

This systematic review and meta-analysis has some strength. It is the first study. Second, we estimated pooled prevalence in CD and UC separately.

Conclusions

The result of this systematic review and meta-analysis showed that the pooled prevalence of migraine in patients with IBD was 19% (95% CI: 15–22%).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Received: 23 Sep 21 Accepted: 14 Jan 22 Published: 27 May 23

References

- 1. Watts D, Satsangi J. The genetic jigsaw of inflammatory bowel disease. Gut 2002;50(Suppl 3):III31-6.
- Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M, Dapoigny M, *et al.* Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study. Eur J Pain 2017;21:1550-60.
- Card TR, Langan SM, Chu TP. Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig Dis Sci 2016;61:2619-26.
- 4. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982-92.
- Vavricka SR, Brun L, Ballabeni P, Pittet V, Vavricka BM, Zeitz J, *et al.* Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011;106:110-9.
- Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn's disease. South Med J 1997;90:606-10.
- 7. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
- 8. Cheraghi SC, Daryani NE, Ghabaee M. A survey on migraine prevalence in patients with inflammatory bowel disease-A single centre experience. Middle East J Dig Dis 2016;8:282-8.
- 9. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: Will health politicians now take notice? J Headache Pain 2018;19:17.
- Ford S, Finkel AG, Isaacs KL. Migraine in patients with inflammatory bowel disorders. J Clin Gastroenterol 2009;43:499.

Olfati, et al.: Migraine in inflammatory bowel disease

- 11. Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW, *et al.* Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013;53:344-55.
- Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, *et al.* Panethnic differences in blood pressure in Europe: A systematic review and meta-analysis. PLoS One 2016;11:e0147601.
- Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa: Ottawa Hospital Research Institute; 2011. p. 1-12.
- Leitão AM, Junior HL, Araújo DF, Braga LL, Souza MH, Barbosa AM, *et al.* Neuropathy and primary headaches affect different subgroups of inflammatory bowel disease patients. Neurol Sci 2021;42:935-42.
- Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: Prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol 2017;29:916-25.
- Anadol Kelleci U, Calhan T, Sahin A, Kahraman R, Ozdil K, Sokmen HM, *et al.* The Prevalence of headache in Crohn's disease: Single-center experience. Gastroenterol Res Pract 2016;2016:6474651.
- Ghersin I, Khateeb N, Katz LH, Daher S, Shamir R, Assa A. Comorbidities in adolescents with inflammatory bowel disease: Findings from a population-based cohort study. Pediatr Res 2020;87:1256-62.
- Belkaid Y, Naik S. Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol 2013;14:646-53.
- Vanmolkot FH, Van Bortel LM, de Hoon JN. Altered arterial function in migraine of recent onset. Neurology 2007;68:1563-70.
- Sadeghniiat K, Rajabzadeh A, Ghajarzadeh M, Ghafarpour M. Sleep quality and depression among patients with migraine. Acta Med Iran 2013;51:784-8.
- Mirmosayyeb O, Shaygannejad V, Ghajarzadeh M. Comparison of psychological difficulties in patients with migraine and epilepsy using PARADISE-24 questionnaire. J Multidiscip Healthc 2020;13:609-13.
- 22. Jalilian R, Ghajarzadeh M, Fateh R, Togha M, Sahraian MA,

Azimi A. Comparison of sleep quality in women with migraine moreover, multiple sclerosis. Acta Med Iran 2014;52:690-3.

- Cavestro C, Ferrero M. Migraine in systemic autoimmune diseases. Endocr Metab Immune Disord Drug Targets 2018;18:124-34.
- 24. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: Results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 2020;21:1-16.
- El-Sonbaty HA-E, Zarad CA, Mohamed MR, Elmaaty A, Ahmed A. Migraine in patients with rheumatoid arthritis and its relation to disease activity. Egypt J Neurol Psychiatr Neurosurg 2021;57:1-10.
- Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis. J Clin Neurosci 2020;79:33-8.
- Mathieu S, Couderc M, Pereira B, Dubost J-J, Malochet-Guinamand S, Tournadre A, *et al.* Prevalence of migraine and neuropathic pain in rheumatic diseases. J Clin Med 2020;9:1890.
- O'Mahony SM, Clarke G, Borre Y, Dinan T, Cryan J. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 2015;277:32-48.
- 29. Hamel E, Currents H. Serotonin and migraine: Biology and clinical implications. Cephalalgia 2007;27:1293-300.
- Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, *et al.* Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64.
- Sarchielli P, Floridi A, Mancini M, Rossi C, Coppola F, Baldi A, et al. NF-κB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia 2006;26:1071-9.
- Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J. Mmp-9 immunoreactivity in acute migraine. Headache 2007;47:698-702.
- Vanmolkot F, Hoon JD. Increased C-reactive protein in young adult patients with migraine. Cephalalgia 2007;27:843-6.